Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer

Michael P. Lux, Andreas D. Hartkopf, Tanja N. Fehm, Manfred Welslau, Volkmar Müller, Florian Schütz, Peter A. Fasching*, Wolfgang Janni, Isabell Witzel, Christoph Thomssen, Milena Beierlein, Erik Belleville, Michael Untch, Marc Thill, Hans Tesch, Nina Ditsch, Bahriye Aktas, Maggie Banys-Paluchowski, Cornelia Kolberg-Liedtke, Achim WöckelHans Christian Kolberg, Nadia Harbeck, Rupert Bartsch, Andreas Schneeweiss, Johannes Ettl, Rachel Würstlein, David Krug, Florin Andrei Taran, Diana Lüftner, Elmar Stickeler

*Corresponding author for this work
1 Citation (Scopus)

Abstract

In recent years, a number of new therapies have led to advances in the treatment of patients with advanced breast carcinoma. These substances are mainly CDK4/6 inhibitors and other substances that can overcome endocrine resistance, oral selective estrogen receptor degraders, antibody drug conjugates (ADCs), and PARP inhibitors. This review summarizes and evaluates the latest study results that have been published in recent months. This includes the overall survival data of the Destiny-Breast03 study, the first analysis of the CAPItello-291 study, the comparison of CDK4/6 inhibitor treatment with chemotherapy in the first line of therapy (RIGHT Choice study), the first analysis of the Destiny-Breast02 study in the treatment setting after T-DM1 treatment, and the first analysis of the Serena-2 study. Most of these studies have the potential to significantly change the therapeutic landscape for patients with advanced breast carcinoma and show that the continued rapid development of new therapies is always producing new results.

Original languageEnglish
JournalGeburtshilfe und Frauenheilkunde
Volume83
Issue number6
Pages (from-to)664-672
Number of pages9
ISSN0016-5751
DOIs
Publication statusPublished - 13.04.2023

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)
  • Centers: University Cancer Center Schleswig-Holstein (UCCSH)

DFG Research Classification Scheme

  • 205-21 Gynaecology and Obstetrics

Cite this